Siponimod shows promise in phase III trial for secondary progressive MS
September 5, 2016In an announcement made on 25 August, the pharmaceutical company Novartis said experimental medication siponimod was able to reduce the risk of disability progression in people with secondary progressive MS. To read more, click on the link below:
Siponimod shows promise in phase III trial for secondary progressive MS
Article courtesy of MS Research Australia www.msra.org.au